METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New timing of chemo drugs could boost pancreatic cancer response
Disease control Recruiting nowThis study tests a new way of giving two chemotherapy drugs (gemcitabine and nab-paclitaxel) to people with pancreatic cancer that has spread. The goal is to see if changing the timing of the infusion helps shrink tumors better. About 67 participants will be enrolled, and the stu…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Anne Noonan • Aim: Disease control
Last updated May 17, 2026 03:26 UTC
-
New hope for pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding the targeted drug panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or cannot be removed will receive either chemo alone or che…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated May 17, 2026 03:24 UTC
-
New hope for pancreatic cancer: experimental combo targets tough tumors
Disease control Recruiting nowThis study tests a new drug (BMS-986340) combined with immunotherapy (nivolumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer that has spread or returned. The goal is to see if the combination is safe and shrinks tumors. Ab…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug TR-002 tested for tough-to-treat cancers
Disease control Recruiting nowThis early-stage study tests a new chemotherapy drug, TR-002, in about 52 people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. The study also looks at whether the drug can shr…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New radio wave device tested alongside chemo for tough pancreatic cancer
Disease control Recruiting nowThis study tests whether adding a special device that delivers radio waves (AM RF EMF) to standard chemotherapy can help people with metastatic pancreatic cancer live longer without the disease getting worse. About 30 adults with advanced pancreatic cancer will receive the combin…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for pancreatic cancer? trial tests two drug combos Head-to-Head
Disease control Recruiting nowThis study tests two different chemotherapy combinations in people with advanced pancreatic cancer that has spread or cannot be removed by surgery. About 52 participants will be randomly assigned to receive either NALIRIFOX or a modified version of gemcitabine, nab-paclitaxel, an…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated May 12, 2026 13:44 UTC
-
Light-activated therapy may boost immune attack on hard-to-treat pancreatic cancer
Disease control Recruiting nowThis study tests a new combination for people with pancreatic cancer that cannot be surgically removed. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab) plus standard chemotherapy. The goal is to see if this approach shri…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New hope for pancreatic cancer: tiny particles deliver Gene-Targeting therapy
Disease control Recruiting nowThis early-phase study tests a new treatment called iExosomes for people with metastatic pancreatic cancer that has a specific mutation in the KRAS gene (G12D). The treatment uses tiny particles from stem cells to deliver a molecule that blocks the mutated gene's activity. The st…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New hope for tough pancreatic cancer: targeted drug combo tested in phase 3 trial
Disease control Recruiting nowThis study tests whether adding the experimental drug setidegrasib to standard chemotherapy helps people with a specific genetic form of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 614 adults whose cancer has spread and cannot be removed by surgery will rec…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC
-
Virtual coaching aims to ease the burden of pancreatic cancer for patients and families
Symptom relief Recruiting nowThis study tests whether telehealth self-management coaching sessions can improve quality of life for people with metastatic pancreatic cancer and their family caregivers. The program focuses on managing physical symptoms, emotional well-being, social health, and spiritual needs.…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 13, 2026 16:04 UTC